Bulletin
Investor Alert

New York Markets Close in:

BioNTech SE ADR

NAS: BNTX

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Mar 24, 2023, 3:48 p.m.

/zigman2/quotes/214419716/composite

$

127.76

Change

-1.63 -1.26%

Volume

Volume 459,204

Real time quotes

/zigman2/quotes/214419716/composite

Previous close

$ 129.39

$ 127.76

Change

-1.63 -1.26%

Day low

Day high

$127.23

$129.39

Open

52 week low

52 week high

$117.08

$189.07

Open

Company Description

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem T...

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Valuation

P/E Current

2.85

P/E Ratio (with extraordinary items)

3.01

P/E Ratio (without extraordinary items)

5.17

Price to Sales Ratio

2.98

Price to Book Ratio

4.62

Price to Cash Flow Ratio

63.67

Enterprise Value to EBITDA

1.47

Enterprise Value to Sales

1.52

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

7,277,773.00

Income Per Employee

3,947,287.00

Receivables Turnover

3.14

Total Asset Turnover

2.15

Liquidity

Current Ratio

4.32

Quick Ratio

4.17

Cash Ratio

0.49

Profitability

Gross Margin

99.49

Operating Margin

92.93

Pretax Margin

79.29

Net Margin

54.24

Return on Assets

116.75

Return on Equity

160.03

Return on Total Capital

263.18

Return on Invested Capital

155.15

Capital Structure

Total Debt to Total Equity

2.53

Total Debt to Total Capital

2.47

Total Debt to Total Assets

1.90

Long-Term Debt to Equity

1.44

Long-Term Debt to Total Capital

1.41

Officers and Executives

Name Age Officer Since Title
Mr. Helmut Jeggle 51 2008 Chairman-Supervisory Board
Dr. Ugur Sahin 56 2008 Chief Executive Officer
Dr. Sierk Pötting 48 2014 Chief Operating & Financial Officer
Mr. Jens Holstein 56 2021 Chief Financial Officer
Dr. Özlem Türeci 54 2008 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
/news/latest/company/us/bntx

MarketWatch News on BNTX

  1. Moderna promises to keep COVID vaccine free

    5:58 p.m. Feb. 15, 2023

    - Claudia Assis

  2. Pfizer Is Moving Beyond Covid. Why Its Stock Is a Buy.

    9:53 a.m. Feb. 5, 2023

    - Andrew Bary

  3. Is pharma M&A making a comeback?

    7:22 a.m. Jan. 13, 2023

    - Jaimy Lee

  4. BioNTech to acquire AI company

    7:53 a.m. Jan. 10, 2023

    - Jaimy Lee

  5. Loading more headlines...
/news/nonmarketwatch/company/us/bntx

Other News on BNTX

  1. Moderna to Price Its Covid-19 Vaccine at $130 a Dose

    2:34 a.m. March 23, 2023

    - The Wall Street Journal Interactive Edition

  2. China Approves First Homegrown mRNA Covid-19 Vaccine

    2:34 a.m. March 23, 2023

    - The Wall Street Journal Interactive Edition

  3. Moderna CEO Defends Pricing Plans for Covid Shot

    3:33 a.m. March 7, 2023

    - The Wall Street Journal Interactive Edition

  4. Moderna’s Earnings, Revenue Fall on Fewer Vaccine Sales

    3:33 a.m. Feb. 24, 2023

    - The Wall Street Journal Interactive Edition

  5. Novavax to Sell 1.5 Million More Covid Vaccines to U.S.

    3:32 a.m. Feb. 14, 2023

    - The Wall Street Journal Interactive Edition

  6. Pfizer Expects Drop in Revenue as Vaccine Demand Wanes

    11:59 a.m. Feb. 6, 2023

    - The Wall Street Journal Interactive Edition

  7. Johnson & Johnson Profit Falls 25%

    12:11 p.m. Feb. 6, 2023

    - The Wall Street Journal Interactive Edition

  8. A New U.S. Law Aims to Reduce Drug Prices. But First, It Might Raise Them

    1:32 p.m. Jan. 18, 2023

    - The Wall Street Journal Interactive Edition

  9. J&J Slashes Production of Its Covid-19 Vaccine

    3:33 a.m. Jan. 14, 2023

    - The Wall Street Journal Interactive Edition

  10. China Lifts Ban on Australian Coal in Move to Mend Ties

    8:13 a.m. Jan. 12, 2023

    - The Wall Street Journal Interactive Edition

  11. Moderna Considers Price of $110-$130 for Covid-19 Vaccine

    3:34 a.m. Jan. 10, 2023

    - The Wall Street Journal Interactive Edition

  12. China to Allow Rapid Tests to Confirm Covid Cases

    3:35 a.m. Jan. 7, 2023

    - The Wall Street Journal Interactive Edition

  13. China’s mRNA Covid Vaccine Starts Test Production

    2:28 p.m. Jan. 6, 2023

    - The Wall Street Journal Interactive Edition

  14. Western Covid Medicine to China’s Rescue

    1:12 p.m. Dec. 29, 2022

    - The Wall Street Journal Interactive Edition

  15. Boring Was King of Healthcare in 2022

    3:33 a.m. Dec. 29, 2022

    - The Wall Street Journal Interactive Edition

  16. Beijing’s Parcel Pileup Shows Strain of Zero-Covid Exit

    3:34 a.m. Dec. 16, 2022

    - The Wall Street Journal Interactive Edition

  17. Moderna’s mRNA Cancer Vaccine Shows Promise in Preliminary Study

    3:34 a.m. Dec. 14, 2022

    - The Wall Street Journal Interactive Edition

  18. CDC Backs New Covid Boosters for Youngest Kids

    3:35 a.m. Dec. 10, 2022

    - The Wall Street Journal Interactive Edition

  19. Loading more headlines...

At a Glance

BioNTech SE

An der Goldgrube 12

Mainz, Rheinland-Pfalz 55131

Phone

49 613190840

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

Revenue

$22.43B

Net Income

$12.17B

2021 Sales Growth

3979.4%

Employees

3,082

/news/pressrelease/company/us/bntx

Press Releases on BNTX

  1. Biontech Se $BNTX Proactive Strategies

    2:43 a.m. March 16, 2023

    - Stock Traders Daily

  2. Biontech Se $BNTX Pivots Trading Plans and Risk Controls

    11:36 a.m. March 6, 2023

    - Stock Traders Daily

  3. Biontech Se $BNTX Investment Report

    7:49 p.m. Feb. 24, 2023

    - Stock Traders Daily

  4. Biontech Se (BNTX) Trading Report

    5:08 a.m. Feb. 15, 2023

    - Stock Traders Daily

  5. Trading Biontech Se BNTX With Integrated Risk Controls

    11:34 p.m. Jan. 26, 2023

    - Stock Traders Daily

  6. Biontech Se BNTX Trading Report

    7:34 a.m. Jan. 17, 2023

    - Stock Traders Daily

  7. Trend Tracker for Biontech Se BNTX

    4:47 p.m. Jan. 7, 2023

    - Stock Traders Daily

  8. BioNTech Gains on Vaccine Deal with U.K.

    10:58 a.m. Jan. 6, 2023

    - Baystreet.ca

  9. How To Trade Biontech Se BNTX

    1:47 a.m. Dec. 29, 2022

    - Stock Traders Daily

  10. Loading more headlines...
Link to MarketWatch's Slice.